NCT05905926Phase 3Enrolling by invitation

Safety Study of Tenapanor for the Treatment of Pediatric Patients (6 to Less Than 18 Years Old) With IBS-C

Study sponsor: Ardelyx

Compare the available registry edits below. Primary completion is the date data collection ends for the main study measures; it does not tell you when results will be published.

Open ClinicalTrials.gov record CSV export · Pro

Primary completion2031-07Estimated

Enrollment · participants150Estimated

Source updated2026-06-04Last update listed in the registry record

Version history

Changes to this trial

Last 12 months

Pro unlocks the full available history and CSV export. View Pro features

No recorded changes are available for this view and time period. Our history may be incomplete; this does not establish that the trial stayed unchanged.

Study details

Conditions studied

Irritable Bowel Syndrome With Constipation (IBS-C)

Treatments or interventions studied

TenapanorDrugAlso known as Ibsrela

Primary outcomes · main study measures

measure: Safety Measure Assessment (Adverse Event); description: Incidence of AEs, SAEs and drug related adverse events; timeFrame: 40 weeks; measure: Safety Measure Assessment (ECG); description: Descriptive summaries of ECG parameters (heart rate, PR-interval, QRS-duration, QT-interval, QTc-interval, and RR-interval); timeFrame: 40 weeks

History coverage

Research sample: selected versions from May 2023 onward plus a preceding baseline where available. Only selected fields were retained; endpoint measures were truncated to 300 characters. This is not complete trial or sponsor history. Daily snapshots begin when collection starts.

How to read this history